Vaccitech to Participate at The 33rd Annual Virtual Piper Sandler Healthcare Conference

Rhea-AI Summary

Vaccitech plc (NASDAQ: VACC) announced participation in the 33rd Annual Virtual Piper Sandler Healthcare Conference from November 30 to December 2, 2021. CEO Bill Enright and CFO Georgy Egorov will engage in a pre-recorded fireside chat, available on-demand starting November 22, 2021. Vaccitech specializes in developing immunotherapeutics and vaccines for infectious diseases and cancer, including a co-invented COVID-19 vaccine with the University of Oxford, licensed to AstraZeneca. The company's proprietary platforms promise enhanced immunological responses.

OXFORD, United Kingdom, Nov. 24, 2021 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced that Bill Enright, Chief Executive Officer, and Georgy Egorov, Chief Financial Officer, are participating at the 33^rd Annual Virtual Piper Sandler Healthcare Conference November 30^th to December 2^nd, 2021. A pre-recorded fireside chat with Bill Enright and Georgy Egorov is available at the link below.

Event:	33rd Piper Sandler Annual Healthcare Conference
Fireside Chat:	Virtual on-demand webcast
Time/date:	10 a.m. EST, Nov. 22 and available for approximately 90 days
Webcast:	Events section of the Vaccitech website

About Vaccitech plc
Vaccitech is a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer. The company’s proprietary platform comprises proprietary modified simian adenoviral vectors, known as ChAdOx1 and ChAdOx2, as well as the well-validated Modified Vaccinia Ankara, or MVA, boost vector, both with demonstrable tolerability profiles and without the ability to replicate in humans. The combination of a ChAdOx prime treatment with subsequent MVA boost has consistently generated significantly higher magnitudes of CD8+ T cells compared with other technologies and approaches. The company has a broad pipeline of both clinical and preclinical stage therapeutic programs in solid tumors and viral infections and prophylactic viral vaccine programs. Vaccitech co-invented a COVID-19 vaccine with the University of Oxford, now approved for use in many territories and exclusively licensed worldwide to AstraZeneca through Oxford University Innovation, or OUI. Vaccitech is entitled to receive a share of the milestones and royalty income received by OUI from AstraZeneca.

Vaccitech Media contacts:
Katja Stout, Scius Communications (EU)
Direct: +44 (0) 7789435990
Email: katja@sciuscommunications.com

Robert Flamm, Ph.D.
212-213-0006 ext. 364
Email: rflamm@burnsmc.com

Henry Hodge, Vaccitech
Email: henry.hodge@vaccitech.co.uk

FAQ

When will Vaccitech participate in the Piper Sandler Healthcare Conference?

Vaccitech will participate in the 33rd Annual Virtual Piper Sandler Healthcare Conference from November 30 to December 2, 2021.

Who will represent Vaccitech at the Piper Sandler Conference?

CEO Bill Enright and CFO Georgy Egorov will represent Vaccitech at the conference.

Can I access the Vaccitech fireside chat?

Yes, the fireside chat will be available on-demand starting November 22, 2021, for approximately 90 days.

What is the focus of Vaccitech's development?

Vaccitech focuses on developing novel immunotherapeutics and vaccines for infectious diseases and cancer.

What vaccine did Vaccitech co-invent?

Vaccitech co-invented a COVID-19 vaccine in collaboration with the University of Oxford.